Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours (NCT07446855)
A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.
Who can join: Review the eligibility criteria below.
Location: Research Site — New York, New York
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Research Site — New York, New York
- Research Site — Providence, Rhode Island
- Research Site — Houston, Texas
- Research Site — Fairfax, Virginia
- Research Site — Melbourne,
- Research Site — Westmead,
- Research Site — Chūōku,
- Research Site — Kashiwa,
- Research Site — Seoul,
- Research Site — Seoul,
- Research Site — Barcelona,
- Research Site — Barcelona,
- Research Site — Barcelona,
- Research Site — Logroño,
- Research Site — Pozuelo de Alarcón,
- Research Site — Seville,
- Research Site — Cambridge,
- Research Site — London,
- Research Site — Sutton,
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumours
- A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine — Beverly Hills, California
- A Study of BI 3810944 in Patients With Advanced Cancer — Louisville, Kentucky
- A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors — Irvine, California
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors — Beverly Hills, California
- Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations — Anchorage, Alaska
Explore by condition: All Solid Tumours clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.